Real World EviDEnce of the EffecTIveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents 12 to <18 Years of Age With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation (DETI-2)
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DETI-2
- Sponsors AbbVie
Most Recent Events
- 01 Jul 2021 Status changed from active, no longer recruiting to completed.
- 26 Feb 2021 Planned End Date changed from 1 Mar 2021 to 16 Jun 2021.
- 26 Feb 2021 Planned primary completion date changed from 1 Mar 2021 to 16 Jun 2021.